DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Clin Cancer Res 1-3-2009; 15: 1612-1622
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.